Sofie Arnetorp

531 total citations · 1 hit paper
17 papers, 260 citations indexed

About

Sofie Arnetorp is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Clinical Psychology. According to data from OpenAlex, Sofie Arnetorp has authored 17 papers receiving a total of 260 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pulmonary and Respiratory Medicine, 6 papers in Physiology and 5 papers in Clinical Psychology. Recurrent topics in Sofie Arnetorp's work include Asthma and respiratory diseases (6 papers), COVID-19 and Mental Health (5 papers) and Chronic Obstructive Pulmonary Disease (COPD) Research (5 papers). Sofie Arnetorp is often cited by papers focused on Asthma and respiratory diseases (6 papers), COVID-19 and Mental Health (5 papers) and Chronic Obstructive Pulmonary Disease (COPD) Research (5 papers). Sofie Arnetorp collaborates with scholars based in United Kingdom, Sweden and United States. Sofie Arnetorp's co-authors include Ralf J.P. van der Valk, Claudia Cabrera, Cassandra Nan, Jennifer K Quint, Chloë I. Bloom, Maarten Beekman, Richard McNulty, Cátia Ferreira, Paul Moss and Eleanor Barnes and has published in prestigious journals such as European Respiratory Journal, International Journal of Environmental Research and Public Health and Age and Ageing.

In The Last Decade

Sofie Arnetorp

15 papers receiving 255 citations

Hit Papers

Impact of COVID-19 on immunocompromised populations durin... 2023 2026 2024 2025 2023 25 50 75
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study
    2023 86 citations Rachael A Evans, Sabada Dube et al. The Lancet Regional Health - Europe profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sofie Arnetorp United Kingdom 6 135 132 83 30 21 17 260
Joseph Rapp United States 8 44 0.3× 52 0.4× 96 1.2× 52 1.7× 69 3.3× 13 241
Ismail Kalla South Africa 7 18 0.1× 37 0.3× 50 0.6× 16 0.5× 33 1.6× 25 152
Efstathia Polychronopoulou United States 9 11 0.1× 33 0.3× 68 0.8× 45 1.5× 43 2.0× 32 242
Francisco Javier Martínez-Peromingo Spain 8 23 0.2× 16 0.1× 51 0.6× 21 0.7× 36 1.7× 24 167
Stefania Sponselli Italy 9 7 0.1× 53 0.4× 103 1.2× 69 2.3× 22 1.0× 17 236
Geeuwke J. de Vries Netherlands 11 85 0.6× 220 1.7× 35 0.4× 13 0.4× 81 3.9× 14 312
Ashwaghosha Parthasarathi India 6 16 0.1× 34 0.3× 30 0.4× 13 0.4× 17 0.8× 28 111
Muthusamy Santhosh Kumar India 9 29 0.2× 6 0.0× 94 1.1× 35 1.2× 9 0.4× 18 179
Sara Ombelet Belgium 5 16 0.1× 18 0.1× 48 0.6× 38 1.3× 42 2.0× 6 186
Yoel Angel Israel 9 8 0.1× 32 0.2× 153 1.8× 11 0.4× 35 1.7× 20 265

Countries citing papers authored by Sofie Arnetorp

Since Specialization
Citations

This map shows the geographic impact of Sofie Arnetorp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sofie Arnetorp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sofie Arnetorp more than expected).

Fields of papers citing papers by Sofie Arnetorp

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sofie Arnetorp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sofie Arnetorp. The network helps show where Sofie Arnetorp may publish in the future.

Co-authorship network of co-authors of Sofie Arnetorp

This figure shows the co-authorship network connecting the top 25 collaborators of Sofie Arnetorp. A scholar is included among the top collaborators of Sofie Arnetorp based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sofie Arnetorp. Sofie Arnetorp is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Aurer, Igor, Paul Moss, Michel Goldman, et al.. (2025). COVID-19 burden of illness in people who are immunocompromised due to cancer: an expert opinion review. The Oncologist. 30(6).
2.
3.
Arnetorp, Sofie, et al.. (2024). Life after Lockdown: An Exploratory Qualitative Study of Behaviors and Impacts of Avoiding COVID-19 in Individuals at High Risk of Severe COVID-19 and Their Caregivers. International Journal of Environmental Research and Public Health. 21(10). 1307–1307. 2 indexed citations
4.
Dube, Sabada, Richard McNulty, Sofie Arnetorp, et al.. (2024). 1848 Risk of severe COVID-19 increases with the number of comorbidities in fully vaccinated individuals aged ≥65: results from INFORM. Age and Ageing. 53(Supplement_1).
5.
6.
Evans, Rachael A, Sabada Dube, Yi Lu, et al.. (2023). Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study. The Lancet Regional Health - Europe. 35. 100747–100747. 86 indexed citations breakdown →
7.
Powell, Patricia, Paul D. Williams, T. A. Herring, et al.. (2023). PCR172 Physical Distancing to Avoid COVID-19 and the Association With Humanistic Burden in Immunocompromised Adults – The Eagle Study. Value in Health. 26(12). S482–S482. 2 indexed citations
8.
Capstick, Toby, Sofie Arnetorp, Eleni Rapsomaniki, et al.. (2023). Healthcare costs associated with short-acting β2-agonists in asthma: observational UK SABINA study. BJGP Open. 7(3). BJGPO.2023.0015–BJGPO.2023.0015. 2 indexed citations
9.
Standaert, Baudouin, Edmund J. Pezalla, Nadia Demarteau, et al.. (2023). Identification of an Optimal COVID-19 Booster Allocation Strategy to Minimize Hospital Bed-Days with a Fixed Healthcare Budget. Vaccines. 11(2). 377–377. 2 indexed citations
10.
11.
Bell, E. J., Sofie Arnetorp, Katja Berg, et al.. (2022). Estimates of the Global Burden of COVID-19 and the Value of Broad and Equitable Access to COVID-19 Vaccines. Vaccines. 10(8). 1320–1320. 13 indexed citations
12.
FitzGerald, J. Mark, et al.. (2020). The cost-effectiveness of as-needed budesonide/formoterol versus low-dose inhaled corticosteroid maintenance therapy in patients with mild asthma in the UK. Respiratory Medicine. 171. 106079–106079. 16 indexed citations
13.
Bloom, Chloë I., Claudia Cabrera, Sofie Arnetorp, et al.. (2020). Asthma-Related Health Outcomes Associated with Short-Acting β2-Agonist Inhaler Use: An Observational UK Study as Part of the SABINA Global Program. Advances in Therapy. 37(10). 4190–4208. 80 indexed citations
14.
Quint, Jennifer K, Sofie Arnetorp, Christer Janson, et al.. (2020). Late Breaking Abstract - Short-acting ß2-agonist use in asthma in Western societies. Data Archiving and Networked Services (DANS). 2629–2629. 1 indexed citations
15.
Cabrera, Claudia, et al.. (2019). SABINA: global programme to evaluate prescriptions and clinical outcomes related to short-acting β2-agonist use in asthma. European Respiratory Journal. 55(2). 1901858–1901858. 41 indexed citations
16.
Sharma, Neha, Balwant Singh, Enrico De Nigris, et al.. (2019). P264 Global treatment guidelines and patterns in COPD: focus on triple therapy. 1 indexed citations
17.
Nielsen, Rune, Hannu Kankaanranta, Leif Bjermer, et al.. (2013). Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Respiratory Medicine. 107(11). 1709–1721. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Joseph Rapp Breakdown of academic impact, for papers by Ismail Kalla Breakdown of academic impact, for papers by Efstathia Polychronopoulou Breakdown of academic impact, for papers by Francisco Javier Martínez-Peromingo Breakdown of academic impact, for papers by Stefania Sponselli Breakdown of academic impact, for papers by Geeuwke J. de Vries Breakdown of academic impact, for papers by Ashwaghosha Parthasarathi Breakdown of academic impact, for papers by Muthusamy Santhosh Kumar Breakdown of academic impact, for papers by Sara Ombelet Breakdown of academic impact, for papers by Yoel Angel
Rankless by CCL
2026